AI-CVD vs Viz AAA
AI Verdict
Choose AI-CVD if…
Choose AI-CVD if your primary objective is broad, opportunistic screening for a range of cardiovascular and multisystem diseases using existing CT scans. This tool is ideal for identifying hidden health risks and enabling early detection without requiring additional imaging, radiation, or disrupting current clinical workflows, providing comprehensive measurements from routine scans.
View AI-CVD →Choose Viz AAA if…
Choose Viz AAA if your focus is on the rapid detection, triage, and coordinated management of suspected Abdominal Aortic Aneurysm (AAA) from CT angiography scans. This solution is best suited for accelerating time-sensitive diagnoses and facilitating immediate care team communication for critical aortic pathologies, streamlining workflows in emergency and vascular surgery settings.
View Viz AAA →Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Head-to-Head
AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.
Usability
Viz AAAViz AAA offers a more comprehensive suite of usability features for care coordination, including real-time alerts, a HIPAA-compliant communication platform, and mobile access to imaging and patient information, which are critical for acute care workflows. While AI-CVD emphasizes minimal workflow disruption by leveraging existing scans and a simple setup, Viz AAA's focus on integrated communication and mobile access for multidisciplinary teams gives it an edge in overall usability for rapid response scenarios.
Clinical Value
AI-CVDAI-CVD offers broader clinical value through its comprehensive opportunistic screening capabilities, extracting insights for multiple cardiovascular and multisystem diseases from existing CT scans, including bone mineral density and liver fat. This allows for early detection and personalized prevention strategies across a wider range of conditions. While Viz AAA provides critical, time-sensitive detection for AAA, AI-CVD's extensive scope for proactive risk assessment gives it a more expansive clinical utility.
Pricing & Value
TieBoth tools require direct contact for specific pricing, making a direct comparison of their cost-effectiveness impossible. While Viz AAA provides a general outline of its subscription model and factors influencing the fee, neither offers public pricing tiers or transparent value propositions. Therefore, without concrete financial details, a definitive winner cannot be determined.
Enterprise Readiness
Viz AAAViz AAA demonstrates stronger enterprise readiness with explicit confirmation of HIPAA compliance and a Business Associate Agreement (BAA). Its features like seamless integration into hospital workflows, real-time alerts, and a HIPAA-compliant communication platform are crucial for large-scale adoption and secure data exchange. Viz.ai's established market presence and dedicated customer success resources further support its enterprise capabilities.
Innovation
AI-CVDAI-CVD exhibits a higher degree of innovation by pioneering a comprehensive opportunistic screening approach that extracts a wide array of cardiovascular and multisystem disease insights from *existing* CT scans, without requiring additional procedures or workflow changes. This transforms routine imaging into a powerful tool for early detection across numerous conditions. While Viz AAA was the first FDA-cleared for AAA detection, AI-CVD's multi-faceted, 'no-touch' screening capability across diverse conditions represents a more foundational shift in leveraging existing data.
Support & Docs
Viz AAAViz AAA offers more robust and transparent support and documentation resources, including a dedicated customer support center with 24/7 urgent support, a comprehensive online knowledge base, and a dedicated customer success team. While AI-CVD provides contact information and a knowledge center, Viz.ai's extensive infrastructure and proactive support offerings indicate a more mature and accessible support ecosystem for enterprise clients.
Feature-by-Feature
Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.
| Feature | AI-CVD | Viz AAA |
|---|---|---|
| Name | AI-CVD | Viz AAA |
| Company | HeartLung Corporation | Viz.ai |
| Description | FDA-cleared, AI-powered quantitative imaging platform that performs opportunistic screening for cardiovascular and multisystem diseases using existing CT scans, enabling early detection of hidden health risks. | First FDA-cleared AI-powered solution for the detection and triage of suspected Abdominal Aortic Aneurysm (AAA) from CT angiography scans, designed to accelerate diagnosis and care coordination. |
| Key Features (Cardiovascular) | Coronary Artery Calcium (CAC) scoring; Aortic wall, aortic valve, and mitral valve calcium analysis; Cardiac chamber volumetry (Left Atrium, Left Ventricle, Right Atrium, Right Ventricle); Epicardial fat volumetry; Aorta and pulmonary artery sizing | AI-powered automatic detection of suspected AAA from CTA scans; Part of the Vizu2122 AORTIC Module for comprehensive aortic pathology solutions |
| Key Features (Workflow/Operational) | Automated CT-derived anatomical and density-based measurements; Opportunistic screening from existing chest and abdominal CT scans; No additional imaging, radiation, contrast, or workflow disruption | Automated triage and prioritization of cases; Integration into existing hospital workflows; Real-time alerts to care teams; HIPAA-compliant communication platform for multidisciplinary teams; Mobile access to high-fidelity imaging and patient information; Designed to accelerate treatment decisions and improve patient outcomes |
| Specialties | Cardiology, Pulmonology, Radiology | Emergency Medicine, Radiology, Vascular Surgery |
Videos
Demos, reviews, and walkthroughs featuring AI-CVD and Viz AAA.